Clinical Trials

42 enrolled

Prostatic Neoplasms

NCT05663710 2026-04-16

Phase 1b/2 Study of Combination 177Lu Girentuximab Plus Cabozantinib and Nivolumab in Treatment naïve Patients With Advanced Clear Cell RCC

100 enrolled

Carcinoma, Renal Cell

NCT05939414 2026-04-16

PSMA-DC

450 enrolled

Oligometastatic Prostate Cancer (OMPC)

NCT06171139 2026-04-16

Tumor Genomic Pre-test Counseling Tool for Black or African-American Men With Prostate Cancer

Phase NA Recruiting

80 enrolled

Prostatic Neoplasms

NCT06347705 2026-04-16

A Study of 2141-V11 in Combination With Standard Treatments in People With Prostate Cancer

57 enrolled

Prostatic Neoplasms

NCT06439225 2026-04-16

OPTION-DDR

236 enrolled

Prostatic Neoplasms

NCT06451614 2026-04-16

HYDROSPACE

230 enrolled

Prostatic Neoplasms

NCT06629779 2026-04-16

A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.

900 enrolled

Metastatic Castration-Resistant Prostate Cancer

NCT06780670 2026-04-16

PSMAcTION

Phase 2/3 Recruiting

443 enrolled

Prostatic Neoplasms

NCT06991556 2026-04-16

An Open-label Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)

150 enrolled

Metastatic Hormone-sensitive Prostate Cancer

NCT07110038 2026-04-16

DEPECA-1 - A Phase II Study to Evaluate a First-line Systemic Therapy With Enfortumab Vedotin Plus Avelumab for Advanced and Metastatic Penile Carcinoma

25 enrolled

Penile Squamous Cell Carcinoma (PSCC)

NCT07206056 2026-04-16

TulmiSTAR-01

188 enrolled

Progressive Metastatic Castrate Resistant Prostate Cancer

NCT07213674 2026-04-16

A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer

750 enrolled

Prostatic Neoplasms

NCT07223424 2026-04-16

PSI-Immune

DermatologicGastrointestinalGenitourinaryGynecologicThoracic

880 enrolled

Adenocarcinoma Of Esophagus, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Squamous Cell, Uterine Cervical Neoplasms, Colitis, Ulcerative, Colonic Neoplasms, Esophageal Neoplasms, Carcinoma, Hepatocellular, Melanoma

NCT07226986 2026-04-16

A Phase Ib/II Open-label Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI in Adult Participants With PSMA-positive mCRPC

123 enrolled

PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC) With Prior Exposure to One Prior ARPI Who Are Candidates for Taxane-based Chemotherapy

NCT07416123 2026-04-16

A Study of GEN1106 in Participants With Solid Tumors

103 enrolled

Carcinoma, Transitional Cell

NCT07532902 2026-04-16

A Study of BMS-986504 With Standard-of-Care Therapy for People With Solid Tumor Cancer

60 enrolled

Carcinoma, Transitional Cell

NCT07534631 2026-04-16

Holmium Laser En-Bloc Resection Versus Conventional Transurethral Resection of Bladder Tumors for Treatment of Non-muscle- Invasive Bladder Cancer

Phase NA Completed

100 enrolled

Phase 2 Active not recruiting

Urinary Bladder Neoplasms

NCT00814021 2026-04-15

Sunitinib in Treating Patients With Kidney Cancer That Has Spread to the Brain

Phase 2 Completed

21 enrolled

CNSGenitourinary

Brain Neoplasms, Carcinoma, Renal Cell, Kidney Neoplasms, Neoplasm Metastasis

NCT00918775 2026-04-15

Follow-up After Metastasectomy in Patients With Kidney Cancer

86 enrolled

Phase EARLY_PHASE1 Completed

Carcinoma, Renal Cell

NCT01868087 2026-04-15

Impact Advanced Recovery® for Radical Cystectomy (RC) Patients: a Pilot Study

30 enrolled

Urinary Bladder Neoplasms

NCT03317158 2026-04-15

ADAPT-BLADDER

55 enrolled

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT03575611 2026-04-15

Stereotactic Body Radiation Therapy in Treating Patients With Oligometastatic Renal Cell Carcinoma

Phase 2 Suspended

123 enrolled

Phase 3 Active not recruiting

Carcinoma, Renal Cell

NCT03661320 2026-04-15

A Study to Compare Chemotherapy Alone Versus Chemotherapy Plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Therapy After Surgery With Nivolumab or Nivolumab and BMS-986205 in Participants With Muscle Invasive Bladder Cancer

855 enrolled

Urinary Bladder Neoplasms

NCT03682289 2026-04-15

Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors

GastrointestinalGenitourinaryGynecologic

89 enrolled

Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Neoplasm Metastasis, Pancreatic Neoplasms, Endometrial Neoplasms

NCT03810651 2026-04-15

Pencil Beam Scanning in Patients With Renal Tumors

Phase EARLY_PHASE1 Recruiting

28 enrolled

Phase 2 Active not recruiting

Carcinoma, Renal Cell, Wilms Tumor

NCT03821792 2026-04-15

Abiraterone Acetate, Prednisone, and Apalutamide in Treating Patients With Hormone-Naive Metastatic Prostate Cancer

60 enrolled

BreastGastrointestinalGenitourinaryGynecologicLymphoid

Prostatic Neoplasms

NCT03935282 2026-04-15

AH-HA

Phase NA Completed

645 enrolled 43 charts

Breast Neoplasms, Cardiovascular Diseases, Hodgkin Disease, Lymphoma, Non-Hodgkin, Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms, Health Behavior, Endometrial Neoplasms

NCT03967977 2026-04-15

Study of Tislelizumab in Combination With Chemotherapy Compared to Chemotherapy Alone for Participants With Urothelial Carcinoma

420 enrolled

Phase EARLY_PHASE1 Completed

Carcinoma, Transitional Cell

NCT04028245 2026-04-15

SPARC-1

17 enrolled

Carcinoma, Renal Cell

NCT04215029 2026-04-15

Lifestyle Intervention for the Reduction of Prostate Cancer Disparities Among African Americans

6 enrolled

Prostatic Neoplasms

NCT04308330 2026-04-15

NYMC195

CNSGastrointestinalGenitourinarySarcoma

30 enrolled

Neoplasms, Germ Cell and Embryonal, Wilms Tumor, Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Ewing, Hepatoblastoma

NCT04396808 2026-04-15

Genomics in Michigan to AdJust Outcomes in Prostate canceR (G-MAJOR) for Men With Newly Diagnosed Favorable Risk Prostate Cancer

805 enrolled

Phase 4 Active not recruiting

Prostatic Neoplasms

NCT04597125 2026-04-15

RADIANT: A Study of Radium-223 Dichloride (Xofigo) vs Enzalutamide or Abiraterone (ARPIs, Androgen Receptor Pathway Inhibitors) in Patients With Prostate Cancer That Has Spread to the Bones (mCRPC, Metastatic Castration-Resistant Prostate Cancer)

654 enrolled

DermatologicGastrointestinalGenitourinaryHead & NeckSarcoma

Metastatic Castrate Resistant Prostate Cancer (mCRPC)

NCT04693377 2026-04-15

Cryoablation Combined With Stereotactic Body Radiation Therapy for the Treatment of Painful Bone Metastases, the CROME Trial

Phase NA Recruiting

40 enrolled

Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Melanoma, Neoplasm Metastasis, Prostatic Neoplasms, Sarcoma, Thyroid Neoplasms, Colorectal Neoplasms

NCT04897321 2026-04-15

B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)

CNSDermatologicGastrointestinalGenitourinarySarcoma

48 enrolled

Adrenal Cortex Neoplasms, Carcinoma, Melanoma, Neoplasms, Germ Cell and Embryonal, Wilms Tumor, Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing, Osteosarcoma, Hepatoblastoma, Sarcoma, Clear Cell, Neurofibrosarcoma, Rhabdoid Tumor, Desmoplastic Small Round Cell Tumor

NCT04905069 2026-04-15

SABRE

500 enrolled

Phase 2 Active not recruiting

Neoplasms, Prostatic Neoplasms

NCT04953104 2026-04-15

ARID1A and/or KDM6A Mutation and CXCL13 Expression

6 enrolled

Phase EARLY_PHASE1 Active not recruiting

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Ureteral Neoplasms, Urethral Neoplasms

NCT05047965 2026-04-15

An Investigational Scan (MRI With Dixon Based Sequences) in Detecting Prostate Cancer

65 enrolled

Prostatic Neoplasms

NCT05055843 2026-04-15

Novel Synthetic T2W MR Imaging and Spin Parameter Mapping Techniques for Screening Prostate Cancer

33 enrolled

Prostatic Neoplasms

NCT05155046 2026-04-15

18F-DCFPyL Imaging as a Method to Assess Treatment Response to Stereotactic Body Radiation Therapy

130 enrolled

GenitourinaryGynecologicThoracic

Localized Prostate Cancer

NCT05397093 2026-04-15

ITIL-306 in Advanced Solid Tumors

Phase 1 Terminated

1 enrolled

Carcinoma, Ovarian Epithelial, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Fallopian Tube Neoplasms

NCT05483868 2026-04-15

A Phase 1, Open-label Trial of Belzupacap Sarotalocan (AU-011) in Bladder Cancer

55 enrolled

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

NCT05581004 2026-04-15

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors

DermatologicGastrointestinalGenitourinaryGynecologicHead & Neck

450 enrolled

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Melanoma, Stomach Neoplasms, Colorectal Neoplasms

NCT05987241 2026-04-15

Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study

Phase 2/3 Recruiting

992 enrolled